Biogen first-quarter sales rise 6.7 percent

April 21 (Reuters) - Biogen Inc's quarterly sales rose 6.7 percent, helped by growing demand for its key oral multiple sclerosis (MS) drug, Tecfidera.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.